Xeris Biopharma (NASDAQ:XERS) Rating Lowered to Hold at Wall Street Zen

Xeris Biopharma (NASDAQ:XERS - Get Free Report) was downgraded by research analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a research note issued on Thursday.

Other research analysts have also issued reports about the company. Jefferies Financial Group reaffirmed a "buy" rating and issued a $6.00 price objective (up from $4.00) on shares of Xeris Biopharma in a report on Wednesday, January 29th. Craig Hallum upped their price objective on Xeris Biopharma from $5.00 to $6.50 and gave the company a "buy" rating in a report on Friday, March 7th. Leerink Partners upped their price objective on Xeris Biopharma from $5.00 to $6.00 and gave the company an "outperform" rating in a report on Friday, March 7th. HC Wainwright reaffirmed a "buy" rating and issued a $8.00 price objective (up from $6.60) on shares of Xeris Biopharma in a report on Friday, March 7th. Finally, Oppenheimer upped their price objective on Xeris Biopharma from $6.00 to $7.00 and gave the company an "outperform" rating in a report on Friday, May 9th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, Xeris Biopharma currently has a consensus rating of "Moderate Buy" and an average price target of $6.25.

Xeris Biopharma Stock Performance

XERS traded down $0.02 during trading hours on Thursday, reaching $4.91. The company's stock had a trading volume of 522,089 shares, compared to its average volume of 1,948,515. Xeris Biopharma has a 52 week low of $1.86 and a 52 week high of $6.07. The company's 50-day moving average is $4.74 and its 200-day moving average is $3.94. The firm has a market cap of $767.07 million, a PE ratio of -10.90 and a beta of 1.10.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.06) earnings per share for the quarter, beating analysts' consensus estimates of ($0.07) by $0.01. The business had revenue of $57.80 million during the quarter, compared to the consensus estimate of $57.61 million. Equities analysts anticipate that Xeris Biopharma will post -0.41 earnings per share for the current fiscal year.

Insider Transactions at Xeris Biopharma

In other news, insider Beth Hecht sold 40,000 shares of the stock in a transaction on Thursday, March 20th. The stock was sold at an average price of $5.43, for a total transaction of $217,200.00. Following the sale, the insider now directly owns 1,353,510 shares of the company's stock, valued at approximately $7,349,559.30. This represents a 2.87% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 6.47% of the stock is currently owned by insiders.

Institutional Trading of Xeris Biopharma

Large investors have recently bought and sold shares of the business. NewEdge Advisors LLC acquired a new stake in Xeris Biopharma in the fourth quarter valued at about $34,000. Apella Capital LLC acquired a new stake in Xeris Biopharma in the first quarter valued at about $55,000. Xponance Inc. acquired a new stake in Xeris Biopharma in the first quarter valued at about $57,000. FORA Capital LLC acquired a new stake in Xeris Biopharma in the first quarter valued at about $60,000. Finally, FNY Investment Advisers LLC acquired a new stake in Xeris Biopharma in the first quarter valued at about $63,000. 42.75% of the stock is owned by institutional investors and hedge funds.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.